Chemosensitivity testing in ovarian cancer - prospects for the future

被引:0
作者
Pogonska, Paulina [1 ]
Wydra, Dariusz [1 ]
Serkies, Krystyna [2 ]
Kobierski, Juliusz [1 ]
Lojkowska, Anna [1 ]
机构
[1] Gdatiskiego Uniwersytetu Med, Klin Ginekol Ginekol Onkol & Endokrynol Ginekol, PL-80402 Gdansk, Poland
[2] Gdatiskiego Uniwersytetu Med, Katedra & Klin Onkol & Radioterapii, PL-80402 Gdansk, Poland
关键词
ovarian cancer; ATP TCA; chemotherapy; chemosensitivity tests; xCELLigence system; individualized therapy; LUMINESCENCE ASSAY; LABEL-FREE; REAL-TIME; CHEMOTHERAPY;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Individualization of treatment on the basis of in vitro chemosensitivity testing constitutes one of the aims of contemporary oncology Although previous studies report advantages resulting from chemosensitivity laboratory tests, the issue remains an area of interest. The aim of this study was to discuss chemosensitivity assay methods of ovarian cancer cells. ATP-TCA (ATP-based tumor chemosensitivity assay) is the most investigated chemosensitivity test in ovarian cancer; with well-documented efficacy Potentially it is possible to use the xCELLigence system to evaluate chemosensitivity of ovarian cancer cells by measuring their colony volume but application of this method remains in the experimental phase. Optimization of ovarian cancer treatment would improve chemotherapy results, thus increasing the overall survival, improving the quality of patient life, decreasing chemotherapy-related toxicity and resulting in economic benefits owing to better drug use.
引用
收藏
页码:695 / 698
页数:4
相关论文
共 26 条
[1]  
ANDREOTTI PE, 1995, CANCER RES, V55, P5276
[2]  
[Anonymous], SEER CANC STAT REV 1
[3]  
Blecharz P, 2012, GINEKOL POL, V83, P353
[4]   American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays [J].
Burstein, Harold J. ;
Mangu, Pamela B. ;
Somerfield, Mark R. ;
Schrag, Deborah ;
Samson, David ;
Holt, Lawrence ;
Zelman, Debra ;
Ajani, Jaffer A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) :3328-3330
[5]  
Caltova Katerina, 2012, Acta Medica (Hradec Kralove), V55, P116
[6]   Correlation between the molecular subtype of breast cancer and the in vitro adenosine triphosphate-based chemosensitivity assay [J].
Chang, Jina ;
Lee, Anbok ;
Lee, Jihyun ;
Lim, Woosung ;
Sung, Sun Hee ;
Moon, Byung-In .
JOURNAL OF THE KOREAN SURGICAL SOCIETY, 2013, 84 (06) :313-320
[7]   A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer [J].
Cree, Ian A. ;
Kurbacher, Christian M. ;
Lamont, Alan ;
Hindley, Andrew C. ;
Love, Sharon .
ANTI-CANCER DRUGS, 2007, 18 (09) :1093-1101
[8]   BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer [J].
Dann, Rebecca Byler ;
DeLoia, Julie A. ;
Timms, Kirsten M. ;
Zorn, Kristin K. ;
Potter, Jennifer ;
Flake, Darl D., II ;
Lanchbury, Jerry S. ;
Krivak, Thomas C. .
GYNECOLOGIC ONCOLOGY, 2012, 125 (03) :677-682
[9]   Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study [J].
Hendlisz, Alain ;
Golfinopoulos, Vassilis ;
Deleporte, Amelie ;
Paesmans, Marianne ;
El Mansy, Hazem ;
Garcia, Camilo ;
Peeters, Marc ;
Annemans, Lieven ;
Vandeputte, Caroline ;
Maetens, Marion ;
Borbath, Ivan ;
Dresse, Damien ;
Houbiers, Ghislain ;
Fried, Michael ;
Awada, Ahmad ;
Piccart, Martine ;
Van Laethem, Jean-Luc ;
Flamen, Patrick .
BMC CANCER, 2013, 13
[10]   Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer [J].
Herzog, Thomas J. ;
Krivak, Thomas C. ;
Fader, Amanda Nickles ;
Coleman, Robert L. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2010, 203 (01) :68.e1-68.e6